Glenn Tilton - AbbVie Insider

AbbVie -- USA Stock  

USD 91.36  1.81  1.94%

Independent Director

Mr. Glenn Fletcher Tilton is the Lead Independent Director of the Company. He was chairman of the Midwest for JPMorgan Chase Co. from 2011 until his retirement in 2014. From October 2010 to December 2012, Mr. Tilton also served as the nonexecutive chairman of the board of United Continental Holdings, Inc. From September 2002 to October 2010, he served as chairman, president and chief executive officer of UAL Corporationrationration, and chairman and chief executive officer of United Air Lines, Inc., its wholly owned subsidiary. Prior to becoming the vice chairman of Chevron Texaco following the merger of Texaco Inc. and Chevron Corporationration, Mr. Tilton enjoyed a 30year multidisciplinary career with Texaco Inc., culminating in his election as chairman and chief executive officer. Mr. Tilton is also a director of Abbott Laboratories and Phillips 66. Mr. Tilton also served on the board of directors of Lincoln National Corporationrationration from 2002 to 2007, of TXU Corporationrationration from 2005 to 2007, of Corning Incorporated from 2010 to 2012, and of United Continental Holdings, Inc. from 2010 to 2012.
Age: 67  Director Since 2013      
847-932-7900  http://www.abbvie.com

Glenn Tilton Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 9.72 % which means that it generated profit of $9.72 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 109.09 % meaning that it created $109.09 on every $100 dollars invested by stockholders.
The company currently holds 37.37 B in liabilities with Debt to Equity (D/E) ratio of 733.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. AbbVie has Current Ratio of 1.24 suggesting that it is in a questionable position to pay out its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Dinesh PaliwalBristol Myers Squibb Company
2013
Giovanni CaforioBristol Myers Squibb Company
2017
John StrattonAbbott Laboratories
2017
Kathi SeifertEli Lilly and Company
1995
Sharad MansukaniEndo International plc
2017
Jackson TaiEli Lilly and Company
2013
Ari BousbibIQVIA Holdings
2016
Deborah NeffBio Rad Laboratories
2011
Christopher CoughlinAllergan plc
2016
James BloemAllergan plc
2013
John ConnaughtonIQVIA Holdings
2008
Michael EvaniskoIQVIA Holdings
2010
Alice SchwartzBio Rad Laboratories
1967
Patricia RussoMerck Co
1995
Robert AlpernAbbott Laboratories
2008
Ron TaylorAllergan plc
2013
Togo WestBristol Myers Squibb Company
2015
Matthew EmmensBristol Myers Squibb Company
2017
Louis DrapeauBio Rad Laboratories
2007
Leonard SchaefferIQVIA Holdings
2008
Terrence KearneyVertex Pharmaceuticals Incorpor
2011

Entity Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company was incorporated in 2012 and is based in North Chicago, Illinois. AbbVie operates under Drug Manufacturers - Major classification in USA and traded on New York Stock Exchange. It employs 29000 people.AbbVie (ABBV) is traded on New York Stock Exchange in USA. It is located in ILLINOIS, U.S.A and employs 29,000 people. AbbVie is listed under Pharmaceutical Products category by Fama And French industry classification.

AbbVie Leadership Team

Richard Gonzalez, Chairman
Thomas Hurwich, President
Frederick Waddell, Director
Robert Alpern, Director
Glenn Tilton, Director
Carlos Alban, EVP
Robert Michael, President
Henry Gosebruch, President
Edward Liddy, Director
Brett Hart, Director
William Chase, CFO
William Burnside, Director
Roxanne Austin, Director
Timothy Richmond, SVP
Laura Schumacher, EVP
Roy Roberts, Director
Michael Severino, President
Azita SalekiGerhardt, President, Ph.D
Edward Rapp, Director

Stock Performance Indicators

Did you try this?

Run Content Syndication Now
   

Content Syndication

Quickly integrate customizable finance content to your own investment portal
View All  Next Launch Content Syndication

BATS Exchange Efficient Frontier

Diversify in USA Market
The main assumption in equity investing is that a higher degree of volatility (or risk) means a higher potential (or expected) return on investment. Conversely, investors who take on a low degree of risk have a low expection for return.
Diversify Portfolios
You can create optimal portfolios in USA market or optimize your existing portfolio in one of two ways: 1) For any level of risk, select the one which has the highest expected return. 2) For any expected return, select the one which has the lowest volatility.
Diversify Portfolios
Check also Trending Equities. Please also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.